EA9181 A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia (ALL) in Adults
Abatacept for Immune Checkpoint Inhibitor associated Myocarditis: A Phase 3, Investigator-initiated, randomized, double-blind, placebo-controlled study to evaluate the Efficacy and safety of Abatacept compared to placebo in hospitalized participants with Immune Checkpoint Inhibitor associated Myocarditis.
Randomized Controlled Trial to Compare Persona OsseoTi Keel Cementless TKA vs Persona Keel Cemented TKA A prospective, multi-center study to demonstrate safety, performance, and clinical benefits of the Persona Keel CR knee system including instrumentation
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET)
Phase III Trial Of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone For Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE).
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination with Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recurrent NSCLC (CheckMate-1533, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 1533)
A Randomized Phase III Trial of Checkpoint blockade in Lung cancEr patients in the Adjuvant setting based on pathologic Response following neoadjuvant therapy (CLEAR)
A RANDOMIZED PHASE III TRIAL INCORPORATING PATHOLOGIC COMPLETE RESPONSE IN PARTICIPANTS WITH EARLY STAGE NON SMALL CELL LUNG CANCER TO OPTIMIZE IMMUNOTHERAPY IN THE ADJUVANT SETTING (INSIGHT)
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation” (MajesTEC-4)
A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF LYL314, A CD19/CD20 DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PARTICIPANTS WITH AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
A Phase 3 Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (*HDFN)
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event – ACCLAIM-Lp(a)
